Bayer: slightly reduces losses in 2024
(CercleFinance.com) - Bayer reports Q4 sales of E11.
73bn, down 1.1% y-o-y.
At the same time, quarterly EBITDA before non-recurring items fell by 22.3% to E2.35bn, and EBIT before non-recurring items slumped 56% to E855m.
The group finally recorded a quarterly net loss of E335m, a far cry from the net profit of E1,337m recorded a year earlier for the same period. EPS for Q4 thus came to -E0.34 (vs. +E1.6 in Q4 2023).
For FY 2024, Bayer will post a 2.2% drop in sales, to E46.6bn.
In detail, sales fell by 4.3% in the Crop Science division (to E22,259m), declined by 2.6% in Consumer Health (to ME 5,870) and rose by 0.3% in the Pharmaceuticals division (ME 18,131). Nevertheless, the Group cites "attractive long-term prospects" for its three major activities.
For the full year, EBITDA before exceptional items fell by 13.5% (to E10.1bn) and EBIT before exceptional items by 28.4% (to E5,436m).
In 2024, the group finally recorded a net loss of E2,552m, slightly less than the E2,941m loss in 2023. Annual EPS stands at -E2.6 (vs. -E2.99 in 2023).
CEO Bill Anderson describes fiscal 2025 as 'a pivotal year', likely to be 'more challenging in terms of financial performance, with net sales broadly flat, while earnings and free cash flow will be lower than in the previous year'.
Specifically, Bayer is targeting sales of E45bn to E47bn for FY 2025, representing a variation of -3% to +1% on a currency- and portfolio-adjusted basis.
On a currency-adjusted basis, the company anticipates EBITDA before exceptional items of E9.5 to E10 billion, basic EPS of E4.5 to E5 and free cash flow of E1.5bn to E2.5bn.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
73bn, down 1.1% y-o-y.
At the same time, quarterly EBITDA before non-recurring items fell by 22.3% to E2.35bn, and EBIT before non-recurring items slumped 56% to E855m.
The group finally recorded a quarterly net loss of E335m, a far cry from the net profit of E1,337m recorded a year earlier for the same period. EPS for Q4 thus came to -E0.34 (vs. +E1.6 in Q4 2023).
For FY 2024, Bayer will post a 2.2% drop in sales, to E46.6bn.
In detail, sales fell by 4.3% in the Crop Science division (to E22,259m), declined by 2.6% in Consumer Health (to ME 5,870) and rose by 0.3% in the Pharmaceuticals division (ME 18,131). Nevertheless, the Group cites "attractive long-term prospects" for its three major activities.
For the full year, EBITDA before exceptional items fell by 13.5% (to E10.1bn) and EBIT before exceptional items by 28.4% (to E5,436m).
In 2024, the group finally recorded a net loss of E2,552m, slightly less than the E2,941m loss in 2023. Annual EPS stands at -E2.6 (vs. -E2.99 in 2023).
CEO Bill Anderson describes fiscal 2025 as 'a pivotal year', likely to be 'more challenging in terms of financial performance, with net sales broadly flat, while earnings and free cash flow will be lower than in the previous year'.
Specifically, Bayer is targeting sales of E45bn to E47bn for FY 2025, representing a variation of -3% to +1% on a currency- and portfolio-adjusted basis.
On a currency-adjusted basis, the company anticipates EBITDA before exceptional items of E9.5 to E10 billion, basic EPS of E4.5 to E5 and free cash flow of E1.5bn to E2.5bn.
Copyright (c) 2025 CercleFinance.com. All rights reserved.